A Study Investigating the Pharmacokinetic and Pharmacodynamic Properties and Safety and Tolerability of NNC0471-0119 H When Administered as Bolus in a Continuous Subcutaneous Insulin Infusion Regimen in Participants With Type 2 Diabetes
This study looks at the effect and safety of a new fast-acting insulin (NNC0471-0119) in people with type 2 diabetes when given by an insulin pump. The study tests how fast insulin NNC0471-0119 enters bloodstream, how long it stays there and how much it lowers blood sugar. The new insulin NNC0471-0119 will be compared to insulin aspart. The study will last for about 13-67 days (or a half to 2 months).
• Male or female (sex at birth).
• Age 18-69 years (both inclusive) at the time of signing the informed consent.
• Diagnosed with Type 2 Diabetes (T2D) greater than or equal to (≥) 180 days before screening.
• Treated with any injectable insulin, except once-weekly insulin, ≥ 180 days before screening.
• Current daily insulin treatment between 0.2 and 1.2 Insulin units per kilogram per day \[(I) U/kg/day\] (both inclusive) with or without the following anti-diabetic drugs with stable doses ≥ 90 days prior to the day of screening:
• Any metformin formulation
• Dipeptidyl peptidase-4 inhibitor (DPP4i)
• Sodium-glucose Cotransporter-2 inhibitor (SGLT2i)
• Body mass index (BMI) between 18.5 and 34.9 kg/m2 (both inclusive) at screening.
• HbA1c lesser than or equal to (≤) 9.5%